Lilly, Boehringer in diabetes deal

Eli Lilly and Co. (NYSE:LLY) and Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered to co-develop and co-commercialize a portfolio of diabetes candidates that includes two products from each company. The deal includes Boehringer's linagliptin, a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor, and BI-10773, a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Boehringer submitted regulatory applications for linagliptin for Type II diabetes in 3Q10 in the U.S., Europe and Japan. BI-10773 is expected to start Phase III testing for Type II diabetes this year. The deal also includes Lilly's basal insulin analogs, LY2605541 and LY2963016, which are slated to start Phase III testing for Type I and II diabetes this year. ...